Upregulation of endocannabinoid signaling in vivo restores striatal synaptic plasticity and motor performance in Huntington's disease mice
Open Access
- 24 April 2025
- journal article
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (2) , 149-161
Abstract
Background: Synaptic dysfunction underlies early sensorimotor and cognitive deficits in Huntington's disease (HD) and precedes the degeneration of striatal spiny projection neurons and cortical pyramidal neurons. Movement selection and motor learning, which are impaired early in HD, are regulated by connections between the motor cortex, basal ganglia and thalamus. In particular, plasticity at corticostriatal synapses, including endocannabinoid-mediated long-term depression (LTD), is critical for motor learning. Previously, we found impaired endocannabinoid-mediated LTD, induced by high frequency stimulation (HFS) at corticostriatal synapses in brain slice recordings from pre-manifest HD mouse models, which was corrected by JZL184, an inhibitor of endocannabinoid 2-arachidonoyl glycerol (2-AG) degradation. Objective: Determine the effects of in vivo JZL184 administration on YAC128 HD model and wild-type (WT) littermate mice. Methods: JZL184 was administered to mice orally over a 3-week period and their motor function was assessed using several behavioral tasks. In addition, brain tissue was collected from mice in order to quantify changes in endocannabinoid levels and measure HFS-induced plasticity at corticostriatal synapses. Results: Oral administration of JZL184 significantly increased levels of 2-AG in striatal tissue. While JZL184 treatment had no impact on open field behavior, the treatment eliminated the difference in motor learning on the rotarod task between YAC128 and WT mice. Moreover, HFS-induced striatal plasticity in YAC128 mice was normalized to WT levels after JZL184 treatment. Conclusions: These results suggest a novel target for mitigating early symptoms of HD and support the need for clinical trials of therapies that modulate the endocannabinoid system.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT-178043)
- Huntington Society of Canada
- Canadian Institutes of Health Research
This publication has 69 references indexed in Scilit:
- Endocannabinoid signaling in the central nervous systemGlia, 2022
- A competitive model for striatal action selectionBrain Research, 2019
- Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signalingBrain, Behavior, and Immunity, 2016
- A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s diseaseJournal of Neurology, 2016
- Lack of hippocampal CB1 receptor desensitization by Δ9-tetrahydrocannabinol in aged mice and by low doses of JZL 184Naunyn-Schmiedeberg's Archives of Pharmacology, 2016
- A robust capillary liquid chromatography/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoidsRapid Communications in Mass Spectrometry, 2015
- Differential Role of Anandamide and 2-Arachidonoylglycerol in Memory and Anxiety-like ResponsesBiological Psychiatry, 2011
- A pilot study using nabilone for symptomatic treatment in Huntington's diseaseMovement Disorders, 2009
- Preclinical Huntington's disease: Compensatory brain responses during learningAnnals of Neurology, 2005
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993